论文部分内容阅读
目的探讨腹腔化疗治疗晚期子宫内膜癌的特殊应用价值。方法对1999年1月至2006年12月FIGO手术病理分期Ⅲ期以上26例腹腔化疗的临床资料进行回顾性分析。结果2例子宫内膜癌合并腹水的病人经腹腔化疗腹水消失,择期进行肿瘤细胞减灭术。26例均术后进行腹腔化疗,平均化疗2.7个疗程。总的生存率:2例Ⅳ期分别存活7个月及13个月;1例Ⅲc期病人存活36个月;23例存活至今,5年以上10例,3年以上7例,余均在随访中。结论腹腔化疗在晚期子宫内膜癌的治疗中,近期疗效显著,是否能代替放疗治疗单纯腹腔细胞学阳性的Ⅲa期病人是今后研究的课题。
Objective To investigate the special value of intraperitoneal chemotherapy in the treatment of advanced endometrial cancer. Methods From January 1999 to December 2006, the clinical data of 26 cases with intraperitoneal chemotherapy of stage Ⅲ or above in FIGO surgical stage were analyzed retrospectively. Results 2 cases of endometrial cancer with ascites patients ascites disappeared by intraperitoneal chemotherapy, elective cytoreductive surgery. Twenty-six patients underwent intraperitoneal chemotherapy after an average of 2.7 courses of chemotherapy. The overall survival rate: two cases of stage Ⅳ survived for 7 months and 13 months respectively; 1 case of stage Ⅲc patients survived for 36 months; 23 cases survived so far, 5 years or more in 10 cases and 3 years or more in 7 cases, in. Conclusion Intraperitoneal chemotherapy in the treatment of advanced endometrial cancer, the recent significant effect, whether or not to replace radiotherapy for peritoneal cytology-positive stage Ⅲ a patients is the subject of future research.